NASDAQ:ACORAcorda Therapeutics Stock Price, Forecast & News

Acorda Therapeutics' stock was trading at $1.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ACOR stock has decreased by 27.2% and is now trading at $0.7352. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Acorda Therapeutics.

Acorda Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Acorda Therapeutics.

Acorda Therapeutics Inc (NASDAQ:ACOR) released its quarterly earnings results on Tuesday, May, 5th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.05. The biopharmaceutical company had revenue of $28.10 million for the quarter, compared to analysts' expectations of $39.34 million. Acorda Therapeutics had a negative return on equity of 19.83% and a negative net margin of 131.45%. View Acorda Therapeutics' earnings history.

6 equities research analysts have issued 12 month price objectives for Acorda Therapeutics' shares. Their forecasts range from $1.40 to $12.00. On average, they expect Acorda Therapeutics' stock price to reach $7.07 in the next twelve months. This suggests a possible upside of 861.2% from the stock's current price. View analysts' price targets for Acorda Therapeutics.

Media headlines about ACOR stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Acorda Therapeutics earned a news sentiment score of -1.8 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Acorda Therapeutics.

Acorda Therapeutics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 10,390,000 shares, an increase of 23.8% from the June 15th total of 8,390,000 shares. Based on an average daily trading volume, of 1,920,000 shares, the short-interest ratio is presently 5.4 days. Approximately 22.0% of the company's stock are short sold. View Acorda Therapeutics' Current Options Chain.

Some companies that are related to Acorda Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include InterDigital Wireless (IDCC), Nektar Therapeutics (NKTR), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Applied Materials (AMAT), Intel (INTC), Novavax (NVAX), Western Digital (WDC), salesforce.com (CRM) and FTS International (FTSI).

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ACOR stock can currently be purchased for approximately $0.74.

Acorda Therapeutics has a market capitalization of $35.27 million and generates $192.41 million in revenue each year. The biopharmaceutical company earns $-272,970,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Acorda Therapeutics employs 474 workers across the globe.

The official website for Acorda Therapeutics is www.acorda.com.

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.